Becton Dickinson and Company (BDX) 144.33 $BDX
BD "Dynamic Duos" Education Campaign Aims to Help People Simplify Life with Diabetes
PR Newswire - Wed Apr 22, 7:00AM CDT
Diabetes is a complex disease that can often be overwhelming, creating barriers that may prevent people with diabetes from enjoying the same opportunities as the rest of the population. To help address this issue, BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, is raising awareness of the dynamic role of diabetes educators, whose knowledge and expertise can simplify life for people with diabetes.
BDX: 144.33 (-1.24)
Auto-Injectors Market: Prefilled and Fillable Auto-injectors - Global Industry Analysis 2014 - 2020
M2 - Tue Apr 21, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/25dl9q/autoinjectors) has announced the addition of the "Auto-Injectors Market (Product Types: Prefilled and Fillable Auto-injectors; Therapeutic Applications: Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis and Others; Manufacturing Design: Standardized and Customized Auto-injectors) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global auto-injectors market has been segmented on the basis of product, therapeutic applications, and manufacturing design. Based on product type, the global auto-injectors market is classified into two major segments, namely prefilled auto-injectors and fillable auto-injectors. Based on therapeutic applications, the auto-injectors market is differentiated into four segments: anaphylaxis, multiple sclerosis, rheumatoid arthritis, and others. Depending upon the manufacturing design, the global auto-injectors market is categorized into two segments: standardized auto-injectors and customized auto-injectors. Market revenue in terms of USD million for the period between 2012 and 2020 along with the compound annual growth rate (CAGR %) from 2014 to 2020 are provided for all segments, considering 2013 as the base year. This report also includes recommendations that would help new market entrants in establishing presence and existing market players in expanding their global reach and market share in the auto-injectors market. The report concludes by profiling major players in the auto-injectors market. Company overview, financial overview, product portfolio, business strategy, and recent developments are provided for major market players in the company profile section. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Auto-injectors Market Overview Chapter 4 Global Auto-injectors Market, by Product Type Chapter 5 Global Auto-injectors Market, by Manufacturing Design Chapter 6 Global Auto-injectors Market, by Therapeutic Application Chapter 7 Global Auto-injectors Market, by Geography Chapter 8 Recommendations Chapter 9 Company Profiles - Antares Pharma, Inc. - Becton, Dickinson & Company - Biogen Idec - Mylan, Inc. - Novartis International AG - Pfizer, Inc. - Sanofi - Scandinavian Health Ltd (SHL) Group - Unilife Corporation - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/25...oinjectors
BIIB: 423.57 (+1.46), BDX: 144.33 (-1.24), UNIS: 3.79 (-0.12), PFE: 34.93 (+0.04), ATRS: 2.78 (unch), NVS: 103.45 (-0.62)
Chasing High Dividend Growth Rates For Lower Total Returns
Kurtis Hemmerling - at Seeking Alpha - Mon Apr 20, 5:24AM CDT
RF: 9.73 (+0.15), HSY: 98.33 (+0.31), GPC: 93.02 (+0.57), CAG: 37.52 (-0.09), ED: 61.64 (+0.17), SYY: 37.63 (+0.03), RRD: 19.55 (+0.07), GWW: 243.45 (+0.44), TGT: 81.34 (+0.09), LOW: 73.07 (-0.17), BCR: 175.09 (+0.24), PFE: 34.93 (+0.04), VFC: 73.91 (-0.42), FDO: 79.25 (-0.09), MHFI: 104.25 (+0.69), MO: 52.12 (+0.02), WBA: 87.02 (-0.07), ADP: 85.31 (+0.21), ADM: 48.10 (+0.16), SIAL: 138.92 (+0.17), MRK: 57.69 (+0.03), MCD: 97.84 (+2.97), DOV: 71.89 (-0.04), CTL: 36.27 (-0.03), MMM: 164.67 (+0.67), TE: 19.40 (unch), GE: 26.91 (+0.29), BDX: 144.33 (-1.24), HBAN: 11.03 (-0.14), KMB: 111.85 (-1.30), AON: 97.20 (+0.10), CB: 99.30 (-0.44), KEY: 14.34 (+0.16), K: 63.98 (+0.12), PEP: 97.28 (+0.50), SWK: 98.11 (+1.03), JNJ: 100.43 (+0.13), AVY: 51.78 (+0.28), CMA: 46.05 (+0.62), PPG: 226.40 (-0.65), KO: 41.31 (+0.53), XEL: 34.31 (+0.03), ABT: 48.35 (+1.23), NUE: 46.82 (+0.01), SVU: 11.01 (-0.10), EMR: 58.15 (-0.07), LEG: 44.32 (unch), LLY: 72.30 (+0.09), ITW: 94.44 (+0.02), PLL: 97.75 (-0.81), USB: 42.83 (+0.33), GCI: 35.17 (-0.83), PG: 83.09 (+0.01), JCI: 51.33 (+0.30)
Core Healthcare Companies In My Income And Growth Portfolio
Canadian Dividend Growth Investor - at Seeking Alpha - Sun Apr 19, 7:40PM CDT
BDX: 144.33 (-1.24), GILD: 104.18 (-1.02), BAX: 70.38 (+0.33), AMGN: 169.10 (+0.64), VTR: 72.71 (-0.08)
Becton Dickinson Has Returned 13.7% Since SmarTrend Recommendation (BDX)
Comtex SmarTrend(R) - Wed Apr 15, 5:06PM CDT
SmarTrend identified an Uptrend for Becton Dickinson (NYSE:BDX) on October 6th, 2014 at $123.81. In approximately 6 months, Becton Dickinson has returned 13.74% as of today's recent price of $140.81.
BDX: 144.33 (-1.24)
CareFusion Demonstrates New Medication Safety Technologies At HIMSS15
PR Newswire - Tue Apr 14, 7:30AM CDT
CareFusion, a BD company (NYSE:BDX), today announced it is demonstrating several new medication management technologies at the Healthcare Information Management and Systems Society (HIMSS) annual conference in the Intelligent Health Pavilion and Interoperability Showcase.
BDX: 144.33 (-1.24), CFN: 59.91 (-0.06)
Can Becton, Dickinson And Company Cure Your Portfolio?
Passive Income Pursuit - at Seeking Alpha - Sun Apr 12, 8:30PM CDT
BDX: 144.33 (-1.24), CFN: 59.91 (-0.06)
My K.I.S.S. Dividend Portfolio: 1st Quarter 2015 Update
The Part-time Investor - at Seeking Alpha - Sun Apr 12, 8:03PM CDT
ARLP: 32.70 (+0.25), UTX: 116.96 (+0.01), OKE: 48.94 (+0.88), SYY: 37.63 (+0.03), WMT: 78.43 (+0.40), DEO: 112.35 (+0.02), UGI: 34.60 (+0.03), SPY: 210.63 (+1.03), TGT: 81.34 (+0.09), DE: 88.10 (+0.18), MSFT: 42.99 (+0.36), BBL: 44.84 (+1.29), WPZ: 49.98 (-0.39), HRS: 82.46 (+0.53), HAS: 71.73 (-1.82), NSC: 104.97 (+2.56), COP: 67.88 (-0.14), WFC: 54.67 (+0.39), CSX: 36.26 (+0.91), BA: 151.19 (-2.14), TUP: 67.25 (-2.60), WBA: 87.02 (-0.07), AVA: 33.51 (+0.12), WPC: 65.58 (+0.20), BPL: 78.34 (-0.40), MCD: 97.84 (+2.97), CVX: 109.50 (-0.23), SDY: 78.71 (+0.20), FLIC: 26.29 (+0.21), NVS: 103.45 (-0.62),
72.52 (+0.43), KMI: 44.07 (+0.46), GD: 133.71 (+0.57), GE: 26.91 (+0.29), BDX: 144.33 (-1.24), LMT: 197.63 (+1.34), MDT: 78.01 (+0.93), DLR: 66.29 (-0.23), RTN: 109.65 (+0.82), PTY: 15.70 (unch), CCC: 22.40 (-0.04), O: 49.52 (+0.16), WEC: 50.28 (+0.11), PAA: 50.92 (-0.16), PEP: 97.28 (+0.50), JNJ: 100.43 (+0.13), CINF: 52.16 (-0.03), PAYX: 49.28 (+0.22), NUS: 56.99 (+0.06), QCOM: 68.94 (+0.37), NHI: 68.86 (+0.33), APD: 151.47 (-0.46), EMR: 58.15 (-0.07), SO: 44.48 (+0.06), ITW: 94.44 (+0.02), DRI: 65.20 (-0.09), NLY: 10.27 (+0.02), BIP: 44.65 (-0.04), OHI: 38.52 (+0.22), PG: 83.09 (+0.01), AFL: 64.07 (+0.21), LLL: 123.83 (+0.51)
My Top Health Care Equipment And Supplies Stocks For 2015
Stan Stafford - at Seeking Alpha - Fri Apr 10, 12:52PM CDT
ZMH: 117.49 (+0.12), SIRO: 93.81 (+0.60), ABMD: 69.31 (-0.40), BDX: 144.33 (-1.24), MASI: 34.96 (+0.43), IRIX: 9.81 (-0.08), ALGN: 55.94 (-0.21), CYNO: 31.52 (+0.20), GB: 54.53 (-0.02), EW: 140.87 (+0.39), ANIK: 38.68 (+0.05), ERB: 3.04 (-0.30), BABY: 41.64 (+1.71), GMED: 25.09 (-0.16), BAX: 70.38 (+0.33), STJ: 73.55 (+4.43), INGN: 36.39 (-0.04)
Becton, Dickinson and Company Announces Results of Early Tenders and Consents in Exchange Offers
PR Newswire - Thu Apr 09, 4:46PM CDT
Becton, Dickinson and Company (NYSE: BDX) ("BD"
announced today that, as of 5:00 p.m., New York City time, on April 8, 2015 (the "Early Consent Date" , the aggregate principal amounts listed in the table below of each series of notes listed in the table below (collectively, the "Existing Notes" previously issued by CareFusion Corporation, a wholly owned subsidiary of BD, had been validly tendered and not validly withdrawn in connection with BD's previously announced offers to exchange all validly tendered and accepted notes of each such series of Existing Notes for new notes to be issued by BD (collectively, the "New Notes" , and the related solicitation of consents to amend the indentures governing the Existing Notes. A Registration Statement on Form S-4 (File No. 333-203013) (the "Registration Statement" relating to the issuance of the New Notes was filed with the Securities and Exchange Commission ("SEC" on March 26, 2015, as amended by Amendment No. 1 to Form S-4, filed with the SEC on April 9, 2015, but has not yet been declared effective.
BDX: 144.33 (-1.24)
My Dividend Portfolio: Adding Becton Dickinson
Integrator - at Seeking Alpha - Thu Apr 09, 11:53AM CDT
BDX: 144.33 (-1.24)
Is Great Basin Scientific Just Another Pump And Dump?
The GeoTeam - Seeking Alpha - Wed Apr 08, 12:57PM CDT
GeoInvesting is currently short Great Basic Scientific (NASDAQ: GBSN ), a rapid diagnostic medical test (Nucleic Acid Assay Testing) firm. We first alerted GeoInvesting premium members that we identified red flags associated with GBSN on March 30,...
GNMK: 10.51 (-0.22), GBSN: 4.98 (+1.44), BDX: 144.33 (-1.24), VIVO: 18.89 (+0.01), QDEL: 23.80 (+0.64), CPHD: 53.14 (-0.78), TTOO: 16.10 (-1.15), QGEN: 24.93 (-0.15), HOLX: 33.26 (-0.07), NSPH: 4.05 (+0.10)
Becton Dickinson Up 13.9% Since SmarTrend Uptrend Call (BDX)
Comtex SmarTrend(R) - Wed Apr 08, 11:26AM CDT
SmarTrend identified an Uptrend for Becton Dickinson (NYSE:BDX) on October 6th, 2014 at $123.81. In approximately 6 months, Becton Dickinson has returned 13.89% as of today's recent price of $141.00.
BDX: 144.33 (-1.24)
7% Raise For The Dividend Growth 50
Mike Nadel - at Seeking Alpha - Mon Apr 06, 6:50PM CDT
72.52 (+0.43), KMI: 44.07 (+0.46), MMM: 164.67 (+0.67), GE: 26.91 (+0.29), BDX: 144.33 (-1.24), LMT: 197.63 (+1.34), CLX: 108.89 (-0.08), MKC: 76.89 (+0.68), GPC: 93.02 (+0.57), UTX: 116.96 (+0.01), KMB: 111.85 (-1.30), XOM: 87.46 (+0.58), WMT: 78.43 (+0.40), VIG: 81.35 (+0.37), KRFT: 88.25 (-0.22), O: 49.52 (+0.16), WEC: 50.28 (+0.11), SJM: 117.94 (+0.50), PEP: 97.28 (+0.50), SBUX: 48.33 (-0.04), T: 32.86 (+0.20), JNJ: 100.43 (+0.13), V: 68.01 (+2.66), IBM: 165.36 (+1.10), QCOM: 68.94 (+0.37), TGT: 81.34 (+0.09), CAT: 84.87 (+0.95), MSFT: 42.99 (+0.36), AAPL: 128.62 (+1.71), KO: 41.31 (+0.53), HCP: 42.19 (-0.66), COP: 67.88 (-0.14), SO: 44.48 (+0.06), VOO: 193.09 (+0.95), NEE: 103.29 (-0.11), WBA: 87.02 (-0.07), ADP: 85.31 (+0.21), OHI: 38.52 (+0.22), PG: 83.09 (+0.01), CVX: 109.50 (-0.23), VZ: 49.57 (+0.40), GIS: 56.21 (+0.10), CL: 69.28 (+0.27)
Breakout Labs and Becton, Dickinson and Company Partner to Provide Capital and Expertise to Biomedical Startups
Business Wire - Mon Apr 06, 12:31PM CDT
Breakout Labs, Peter Thiel's philanthropic revolving fund for early-stage science and technology companies, and BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that they have established a strategic relationship to provide additional grant funding and professional expertise to qualifying Breakout Labs portfolio companies.
BDX: 144.33 (-1.24)
Review on Health Care Equipment Stocks -- Baxter Intl., St. Jude Medical, Wright Medical, Becton Dickinson, and Insulet Corp.
PR Newswire - Mon Apr 06, 8:10AM CDT
Editor Note: For more information about this release, please scroll to bottom.
PODD: 30.79 (-0.20), BDX: 144.33 (-1.24), WMGI: 26.08 (-0.14), BAX: 70.38 (+0.33), STJ: 73.55 (+4.43), WMGIZ: 4.12 (-0.03)
BD Announces Live Webcast Of Second Fiscal Quarter Earnings Conference Call
PR Newswire - Mon Apr 06, 7:30AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2015 earnings conference call on Thursday, May 7, 2015, at 8:00 a.m. (ET). BD will issue a press release detailing the quarter's earnings earlier that morning.
BDX: 144.33 (-1.24)
My Strategy For Objective, Emotionless Dividend Growth Investing: Q1 2015 Update
Integrator - at Seeking Alpha - Thu Apr 02, 3:54PM CDT
BDX: 144.33 (-1.24), GE: 26.91 (+0.29), CLX: 108.89 (-0.08), MKC: 76.89 (+0.68), HSY: 98.33 (+0.31), NKE: 100.15 (-0.14), XOM: 87.46 (+0.58), PEP: 97.28 (+0.50), SBUX: 48.33 (-0.04), JNJ: 100.43 (+0.13), FAST: 41.58 (+0.32), COST: 146.98 (-0.36), LOW: 73.07 (-0.17), MSFT: 42.99 (+0.36), YUM: 84.04 (+3.19), CHD: 83.75 (-0.32), DIS: 107.94 (+0.26), COP: 67.88 (-0.14), AMGN: 169.10 (+0.64), WFC: 54.67 (+0.39), CSX: 36.26 (+0.91), MCO: 107.23 (+1.24), ADP: 85.31 (+0.21), MJN: 98.92 (-1.00), USB: 42.83 (+0.33), CVS: 101.23 (-0.18), PG: 83.09 (+0.01), VZ: 49.57 (+0.40), CMCSA: 58.76 (-0.08), CL: 69.28 (+0.27)
Polymerase Chain Reaction (PCR) Market Report - Global Industry Analysis 2014 - 2020
M2 - Tue Mar 31, 10:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2nwk26/polymerase_chain) has announced the addition of the "Polymerase Chain Reaction (PCR) Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The PCR market is broadly classified on the basis of product segments, end-users and application areas. Among the product segments, reagents and consumables remain the most widely used segment with the largest share in the net sales across various companies, considering the global sales of USD 4,072.2 million in 2013. Polymerase chain reaction (PCR) enables DNA sequencing and helps in determining the order of its building blocks. PCR finds applications in disease diagnosis, forensic sciences, and identification of bacteria and viruses. PCR is an excellent technique for rapid detection of microbial contamination and pathogens, including those complicated to culture. These techniques are precise and robust methods that rely on polymerase enzyme to amplify trace amounts of DNA/RNA fragments by creating several identical or near-identical copies. The demand for greater efficiency and productivity in the pharmaceutical industry has led to the growth of this market. The report on the global PCR Market studies the global PCR market in terms of products, end-users, applications and geography. Each of these segments has been analyzed in detail for market trends, recent developments, outlook and opportunities and various applications. The report provides the market size in terms of value (USD million) for each segment and sub-segment for the period from 2012 to 2020, considering the macro- and micro environmental factors. In addition, the compounded annual growth rate (CAGR) of the overall market and the segments has also been included in the report for the forecast period from 2014 to 2020, considering 2012 and 2013 as the base years. The PCR products studied in this report include instruments, and reagents and consumables. Instruments are further classified by type such as standard PCR, quantitative real time PCR (qPCR) and digital PCR (dPCR). Pharmaceutical and biotech industries, clinical diagnostic laboratories, hospitals, academics and public research organizations are the major end-users of the global PCR market. PCR Applications segment has been further categorized as clinical diagnostics, life sciences and others such as forensic sciences, agriculture and nanotoxicity studies. Several players are trying to enter and establish themselves in the PCR market, especially in emerging economies. Major players operating in this market are Affymetrix, Inc., Agilent Technologies, Inc., Sigma Aldrich Corporation, Abbott Laboratories, Beckman Coulter, Bio-Rad Laboratories, GE Healthcare, QIAGEN, Becton Dickinson & Company and Thermo Fischer Scientific. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global PCR, Market Overview Chapter 4 Global Polymerase Chain Reaction Market Revenue, by Products, 2012 - 2020 (USD Million) Chapter 5 Global Polymerase Chain Reaction Market Revenue, by End-user, 2012 - 2020 (USD Million) Chapter 6 Global PCR Market Revenue, by Applications, 2012 - 2020 (USD Million) Chapter 7 Global PCR Market Revenue, by Geography, 2012-2020 (USD Million) Chapter 8 Recommendations Chapter 9 Company Profiles - Abbott Laboratories - Affymetrix, Inc. - Agilent Technologies, Inc. - Beckman Coulter, Inc - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - F. Hoffmann-La Roche Ltd. - GE Healthcare - QIAGEN - Sigma-Aldrich Co. LLC. - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/2n...rase_chain
ABT: 48.35 (+1.23), BDX: 144.33 (-1.24), A: 42.71 (-0.18), AFFX: 12.57 (-0.13)
The Best Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Mon Mar 30, 9:19AM CDT
OCR: 84.52 (+3.45), ELLI: 57.00 (-0.45), JCOM: 70.72 (-0.38), CAH: 91.50 (+1.15), AET: 107.95 (-0.41), BABY: 41.64 (+1.71), DFT: 32.24 (-0.18), NLNK: 53.12 (-0.07), HSIC: 141.11 (+1.14), MNK: 122.95 (-2.22), CAVM: 73.16 (+0.39), HAS: 71.73 (-1.82), BCR: 175.09 (+0.24), MCHP: 49.30 (+0.08), MYL: 72.40 (-1.67), NXPI: 102.69 (+1.45), EV: 43.60 (+0.19), NVDA: 22.31 (+0.25), LVLT: 54.24 (-0.04), CBRL: 137.40 (-1.10), MTSI: 34.46 (-0.27), AZO: 693.41 (+2.68), EQIX: 244.78 (+1.00), IRWD: 15.07 (-0.19), AVB: 170.64 (+1.59), KNX: 32.62 (+0.07), HAE: 42.33 (-0.21), FSL: 41.53 (+0.49), FHN: 14.49 (+0.06), BDX: 144.33 (-1.24), ACT: 295.22 (+0.69), F: 15.91 (+0.09), AON: 97.20 (+0.10), NUVA: 43.38 (+0.10), CDW: 38.93 (+0.21), ANTM: 152.84 (-0.04), APH: 56.81 (-1.35), INFA: 47.92 (-0.03), EXAM: 42.52 (-0.16), LII: 107.70 (+2.09), BJRI: 50.54 (-1.00), BDN: 14.90 (+0.14), DPZ: 99.80 (+0.40), FL: 60.00 (-0.08), DLX: 69.57 (+0.47), ABT: 48.35 (+1.23), BMR: 21.37 (+0.14), HCN: 75.44 (+0.21), DIOD: 28.02 (+0.12), LEG: 44.32 (unch), DIS: 107.94 (+0.26), GLW: 22.44 (-0.17), MAR: 80.79 (+0.32), ASML: 107.81 (+10.06), IMAX: 37.51 (+0.51), CNC: 70.90 (+0.12), CTAS: 82.05 (+0.01), FLO: 22.50 (-0.03), CRM: 67.71 (+0.33)
BD "Dynamic Duos" Education Campaign Aims to Help People Simplify Life with Diabetes
PR Newswire - Wed Apr 22, 7:00AM CDT
Diabetes is a complex disease that can often be overwhelming, creating barriers that may prevent people with diabetes from enjoying the same opportunities as the rest of the population. To help address this issue, BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, is raising awareness of the dynamic role of diabetes educators, whose knowledge and expertise can simplify life for people with diabetes.
BDX: 144.33 (-1.24)
Auto-Injectors Market: Prefilled and Fillable Auto-injectors - Global Industry Analysis 2014 - 2020
M2 - Tue Apr 21, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/25dl9q/autoinjectors) has announced the addition of the "Auto-Injectors Market (Product Types: Prefilled and Fillable Auto-injectors; Therapeutic Applications: Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis and Others; Manufacturing Design: Standardized and Customized Auto-injectors) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global auto-injectors market has been segmented on the basis of product, therapeutic applications, and manufacturing design. Based on product type, the global auto-injectors market is classified into two major segments, namely prefilled auto-injectors and fillable auto-injectors. Based on therapeutic applications, the auto-injectors market is differentiated into four segments: anaphylaxis, multiple sclerosis, rheumatoid arthritis, and others. Depending upon the manufacturing design, the global auto-injectors market is categorized into two segments: standardized auto-injectors and customized auto-injectors. Market revenue in terms of USD million for the period between 2012 and 2020 along with the compound annual growth rate (CAGR %) from 2014 to 2020 are provided for all segments, considering 2013 as the base year. This report also includes recommendations that would help new market entrants in establishing presence and existing market players in expanding their global reach and market share in the auto-injectors market. The report concludes by profiling major players in the auto-injectors market. Company overview, financial overview, product portfolio, business strategy, and recent developments are provided for major market players in the company profile section. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Auto-injectors Market Overview Chapter 4 Global Auto-injectors Market, by Product Type Chapter 5 Global Auto-injectors Market, by Manufacturing Design Chapter 6 Global Auto-injectors Market, by Therapeutic Application Chapter 7 Global Auto-injectors Market, by Geography Chapter 8 Recommendations Chapter 9 Company Profiles - Antares Pharma, Inc. - Becton, Dickinson & Company - Biogen Idec - Mylan, Inc. - Novartis International AG - Pfizer, Inc. - Sanofi - Scandinavian Health Ltd (SHL) Group - Unilife Corporation - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/25...oinjectors
BIIB: 423.57 (+1.46), BDX: 144.33 (-1.24), UNIS: 3.79 (-0.12), PFE: 34.93 (+0.04), ATRS: 2.78 (unch), NVS: 103.45 (-0.62)
Chasing High Dividend Growth Rates For Lower Total Returns
Kurtis Hemmerling - at Seeking Alpha - Mon Apr 20, 5:24AM CDT
RF: 9.73 (+0.15), HSY: 98.33 (+0.31), GPC: 93.02 (+0.57), CAG: 37.52 (-0.09), ED: 61.64 (+0.17), SYY: 37.63 (+0.03), RRD: 19.55 (+0.07), GWW: 243.45 (+0.44), TGT: 81.34 (+0.09), LOW: 73.07 (-0.17), BCR: 175.09 (+0.24), PFE: 34.93 (+0.04), VFC: 73.91 (-0.42), FDO: 79.25 (-0.09), MHFI: 104.25 (+0.69), MO: 52.12 (+0.02), WBA: 87.02 (-0.07), ADP: 85.31 (+0.21), ADM: 48.10 (+0.16), SIAL: 138.92 (+0.17), MRK: 57.69 (+0.03), MCD: 97.84 (+2.97), DOV: 71.89 (-0.04), CTL: 36.27 (-0.03), MMM: 164.67 (+0.67), TE: 19.40 (unch), GE: 26.91 (+0.29), BDX: 144.33 (-1.24), HBAN: 11.03 (-0.14), KMB: 111.85 (-1.30), AON: 97.20 (+0.10), CB: 99.30 (-0.44), KEY: 14.34 (+0.16), K: 63.98 (+0.12), PEP: 97.28 (+0.50), SWK: 98.11 (+1.03), JNJ: 100.43 (+0.13), AVY: 51.78 (+0.28), CMA: 46.05 (+0.62), PPG: 226.40 (-0.65), KO: 41.31 (+0.53), XEL: 34.31 (+0.03), ABT: 48.35 (+1.23), NUE: 46.82 (+0.01), SVU: 11.01 (-0.10), EMR: 58.15 (-0.07), LEG: 44.32 (unch), LLY: 72.30 (+0.09), ITW: 94.44 (+0.02), PLL: 97.75 (-0.81), USB: 42.83 (+0.33), GCI: 35.17 (-0.83), PG: 83.09 (+0.01), JCI: 51.33 (+0.30)
Core Healthcare Companies In My Income And Growth Portfolio
Canadian Dividend Growth Investor - at Seeking Alpha - Sun Apr 19, 7:40PM CDT
BDX: 144.33 (-1.24), GILD: 104.18 (-1.02), BAX: 70.38 (+0.33), AMGN: 169.10 (+0.64), VTR: 72.71 (-0.08)
Becton Dickinson Has Returned 13.7% Since SmarTrend Recommendation (BDX)
Comtex SmarTrend(R) - Wed Apr 15, 5:06PM CDT
SmarTrend identified an Uptrend for Becton Dickinson (NYSE:BDX) on October 6th, 2014 at $123.81. In approximately 6 months, Becton Dickinson has returned 13.74% as of today's recent price of $140.81.
BDX: 144.33 (-1.24)
CareFusion Demonstrates New Medication Safety Technologies At HIMSS15
PR Newswire - Tue Apr 14, 7:30AM CDT
CareFusion, a BD company (NYSE:BDX), today announced it is demonstrating several new medication management technologies at the Healthcare Information Management and Systems Society (HIMSS) annual conference in the Intelligent Health Pavilion and Interoperability Showcase.
BDX: 144.33 (-1.24), CFN: 59.91 (-0.06)
Can Becton, Dickinson And Company Cure Your Portfolio?
Passive Income Pursuit - at Seeking Alpha - Sun Apr 12, 8:30PM CDT
BDX: 144.33 (-1.24), CFN: 59.91 (-0.06)
My K.I.S.S. Dividend Portfolio: 1st Quarter 2015 Update
The Part-time Investor - at Seeking Alpha - Sun Apr 12, 8:03PM CDT
ARLP: 32.70 (+0.25), UTX: 116.96 (+0.01), OKE: 48.94 (+0.88), SYY: 37.63 (+0.03), WMT: 78.43 (+0.40), DEO: 112.35 (+0.02), UGI: 34.60 (+0.03), SPY: 210.63 (+1.03), TGT: 81.34 (+0.09), DE: 88.10 (+0.18), MSFT: 42.99 (+0.36), BBL: 44.84 (+1.29), WPZ: 49.98 (-0.39), HRS: 82.46 (+0.53), HAS: 71.73 (-1.82), NSC: 104.97 (+2.56), COP: 67.88 (-0.14), WFC: 54.67 (+0.39), CSX: 36.26 (+0.91), BA: 151.19 (-2.14), TUP: 67.25 (-2.60), WBA: 87.02 (-0.07), AVA: 33.51 (+0.12), WPC: 65.58 (+0.20), BPL: 78.34 (-0.40), MCD: 97.84 (+2.97), CVX: 109.50 (-0.23), SDY: 78.71 (+0.20), FLIC: 26.29 (+0.21), NVS: 103.45 (-0.62),
72.52 (+0.43), KMI: 44.07 (+0.46), GD: 133.71 (+0.57), GE: 26.91 (+0.29), BDX: 144.33 (-1.24), LMT: 197.63 (+1.34), MDT: 78.01 (+0.93), DLR: 66.29 (-0.23), RTN: 109.65 (+0.82), PTY: 15.70 (unch), CCC: 22.40 (-0.04), O: 49.52 (+0.16), WEC: 50.28 (+0.11), PAA: 50.92 (-0.16), PEP: 97.28 (+0.50), JNJ: 100.43 (+0.13), CINF: 52.16 (-0.03), PAYX: 49.28 (+0.22), NUS: 56.99 (+0.06), QCOM: 68.94 (+0.37), NHI: 68.86 (+0.33), APD: 151.47 (-0.46), EMR: 58.15 (-0.07), SO: 44.48 (+0.06), ITW: 94.44 (+0.02), DRI: 65.20 (-0.09), NLY: 10.27 (+0.02), BIP: 44.65 (-0.04), OHI: 38.52 (+0.22), PG: 83.09 (+0.01), AFL: 64.07 (+0.21), LLL: 123.83 (+0.51) My Top Health Care Equipment And Supplies Stocks For 2015
Stan Stafford - at Seeking Alpha - Fri Apr 10, 12:52PM CDT
ZMH: 117.49 (+0.12), SIRO: 93.81 (+0.60), ABMD: 69.31 (-0.40), BDX: 144.33 (-1.24), MASI: 34.96 (+0.43), IRIX: 9.81 (-0.08), ALGN: 55.94 (-0.21), CYNO: 31.52 (+0.20), GB: 54.53 (-0.02), EW: 140.87 (+0.39), ANIK: 38.68 (+0.05), ERB: 3.04 (-0.30), BABY: 41.64 (+1.71), GMED: 25.09 (-0.16), BAX: 70.38 (+0.33), STJ: 73.55 (+4.43), INGN: 36.39 (-0.04)
Becton, Dickinson and Company Announces Results of Early Tenders and Consents in Exchange Offers
PR Newswire - Thu Apr 09, 4:46PM CDT
Becton, Dickinson and Company (NYSE: BDX) ("BD"
announced today that, as of 5:00 p.m., New York City time, on April 8, 2015 (the "Early Consent Date" , the aggregate principal amounts listed in the table below of each series of notes listed in the table below (collectively, the "Existing Notes" previously issued by CareFusion Corporation, a wholly owned subsidiary of BD, had been validly tendered and not validly withdrawn in connection with BD's previously announced offers to exchange all validly tendered and accepted notes of each such series of Existing Notes for new notes to be issued by BD (collectively, the "New Notes" , and the related solicitation of consents to amend the indentures governing the Existing Notes. A Registration Statement on Form S-4 (File No. 333-203013) (the "Registration Statement" relating to the issuance of the New Notes was filed with the Securities and Exchange Commission ("SEC" on March 26, 2015, as amended by Amendment No. 1 to Form S-4, filed with the SEC on April 9, 2015, but has not yet been declared effective. BDX: 144.33 (-1.24)
My Dividend Portfolio: Adding Becton Dickinson
Integrator - at Seeking Alpha - Thu Apr 09, 11:53AM CDT
BDX: 144.33 (-1.24)
Is Great Basin Scientific Just Another Pump And Dump?
The GeoTeam - Seeking Alpha - Wed Apr 08, 12:57PM CDT
GeoInvesting is currently short Great Basic Scientific (NASDAQ: GBSN ), a rapid diagnostic medical test (Nucleic Acid Assay Testing) firm. We first alerted GeoInvesting premium members that we identified red flags associated with GBSN on March 30,...
GNMK: 10.51 (-0.22), GBSN: 4.98 (+1.44), BDX: 144.33 (-1.24), VIVO: 18.89 (+0.01), QDEL: 23.80 (+0.64), CPHD: 53.14 (-0.78), TTOO: 16.10 (-1.15), QGEN: 24.93 (-0.15), HOLX: 33.26 (-0.07), NSPH: 4.05 (+0.10)
Becton Dickinson Up 13.9% Since SmarTrend Uptrend Call (BDX)
Comtex SmarTrend(R) - Wed Apr 08, 11:26AM CDT
SmarTrend identified an Uptrend for Becton Dickinson (NYSE:BDX) on October 6th, 2014 at $123.81. In approximately 6 months, Becton Dickinson has returned 13.89% as of today's recent price of $141.00.
BDX: 144.33 (-1.24)
7% Raise For The Dividend Growth 50
Mike Nadel - at Seeking Alpha - Mon Apr 06, 6:50PM CDT
72.52 (+0.43), KMI: 44.07 (+0.46), MMM: 164.67 (+0.67), GE: 26.91 (+0.29), BDX: 144.33 (-1.24), LMT: 197.63 (+1.34), CLX: 108.89 (-0.08), MKC: 76.89 (+0.68), GPC: 93.02 (+0.57), UTX: 116.96 (+0.01), KMB: 111.85 (-1.30), XOM: 87.46 (+0.58), WMT: 78.43 (+0.40), VIG: 81.35 (+0.37), KRFT: 88.25 (-0.22), O: 49.52 (+0.16), WEC: 50.28 (+0.11), SJM: 117.94 (+0.50), PEP: 97.28 (+0.50), SBUX: 48.33 (-0.04), T: 32.86 (+0.20), JNJ: 100.43 (+0.13), V: 68.01 (+2.66), IBM: 165.36 (+1.10), QCOM: 68.94 (+0.37), TGT: 81.34 (+0.09), CAT: 84.87 (+0.95), MSFT: 42.99 (+0.36), AAPL: 128.62 (+1.71), KO: 41.31 (+0.53), HCP: 42.19 (-0.66), COP: 67.88 (-0.14), SO: 44.48 (+0.06), VOO: 193.09 (+0.95), NEE: 103.29 (-0.11), WBA: 87.02 (-0.07), ADP: 85.31 (+0.21), OHI: 38.52 (+0.22), PG: 83.09 (+0.01), CVX: 109.50 (-0.23), VZ: 49.57 (+0.40), GIS: 56.21 (+0.10), CL: 69.28 (+0.27) Breakout Labs and Becton, Dickinson and Company Partner to Provide Capital and Expertise to Biomedical Startups
Business Wire - Mon Apr 06, 12:31PM CDT
Breakout Labs, Peter Thiel's philanthropic revolving fund for early-stage science and technology companies, and BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that they have established a strategic relationship to provide additional grant funding and professional expertise to qualifying Breakout Labs portfolio companies.
BDX: 144.33 (-1.24)
Review on Health Care Equipment Stocks -- Baxter Intl., St. Jude Medical, Wright Medical, Becton Dickinson, and Insulet Corp.
PR Newswire - Mon Apr 06, 8:10AM CDT
Editor Note: For more information about this release, please scroll to bottom.
PODD: 30.79 (-0.20), BDX: 144.33 (-1.24), WMGI: 26.08 (-0.14), BAX: 70.38 (+0.33), STJ: 73.55 (+4.43), WMGIZ: 4.12 (-0.03)
BD Announces Live Webcast Of Second Fiscal Quarter Earnings Conference Call
PR Newswire - Mon Apr 06, 7:30AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2015 earnings conference call on Thursday, May 7, 2015, at 8:00 a.m. (ET). BD will issue a press release detailing the quarter's earnings earlier that morning.
BDX: 144.33 (-1.24)
My Strategy For Objective, Emotionless Dividend Growth Investing: Q1 2015 Update
Integrator - at Seeking Alpha - Thu Apr 02, 3:54PM CDT
BDX: 144.33 (-1.24), GE: 26.91 (+0.29), CLX: 108.89 (-0.08), MKC: 76.89 (+0.68), HSY: 98.33 (+0.31), NKE: 100.15 (-0.14), XOM: 87.46 (+0.58), PEP: 97.28 (+0.50), SBUX: 48.33 (-0.04), JNJ: 100.43 (+0.13), FAST: 41.58 (+0.32), COST: 146.98 (-0.36), LOW: 73.07 (-0.17), MSFT: 42.99 (+0.36), YUM: 84.04 (+3.19), CHD: 83.75 (-0.32), DIS: 107.94 (+0.26), COP: 67.88 (-0.14), AMGN: 169.10 (+0.64), WFC: 54.67 (+0.39), CSX: 36.26 (+0.91), MCO: 107.23 (+1.24), ADP: 85.31 (+0.21), MJN: 98.92 (-1.00), USB: 42.83 (+0.33), CVS: 101.23 (-0.18), PG: 83.09 (+0.01), VZ: 49.57 (+0.40), CMCSA: 58.76 (-0.08), CL: 69.28 (+0.27)
Polymerase Chain Reaction (PCR) Market Report - Global Industry Analysis 2014 - 2020
M2 - Tue Mar 31, 10:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2nwk26/polymerase_chain) has announced the addition of the "Polymerase Chain Reaction (PCR) Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The PCR market is broadly classified on the basis of product segments, end-users and application areas. Among the product segments, reagents and consumables remain the most widely used segment with the largest share in the net sales across various companies, considering the global sales of USD 4,072.2 million in 2013. Polymerase chain reaction (PCR) enables DNA sequencing and helps in determining the order of its building blocks. PCR finds applications in disease diagnosis, forensic sciences, and identification of bacteria and viruses. PCR is an excellent technique for rapid detection of microbial contamination and pathogens, including those complicated to culture. These techniques are precise and robust methods that rely on polymerase enzyme to amplify trace amounts of DNA/RNA fragments by creating several identical or near-identical copies. The demand for greater efficiency and productivity in the pharmaceutical industry has led to the growth of this market. The report on the global PCR Market studies the global PCR market in terms of products, end-users, applications and geography. Each of these segments has been analyzed in detail for market trends, recent developments, outlook and opportunities and various applications. The report provides the market size in terms of value (USD million) for each segment and sub-segment for the period from 2012 to 2020, considering the macro- and micro environmental factors. In addition, the compounded annual growth rate (CAGR) of the overall market and the segments has also been included in the report for the forecast period from 2014 to 2020, considering 2012 and 2013 as the base years. The PCR products studied in this report include instruments, and reagents and consumables. Instruments are further classified by type such as standard PCR, quantitative real time PCR (qPCR) and digital PCR (dPCR). Pharmaceutical and biotech industries, clinical diagnostic laboratories, hospitals, academics and public research organizations are the major end-users of the global PCR market. PCR Applications segment has been further categorized as clinical diagnostics, life sciences and others such as forensic sciences, agriculture and nanotoxicity studies. Several players are trying to enter and establish themselves in the PCR market, especially in emerging economies. Major players operating in this market are Affymetrix, Inc., Agilent Technologies, Inc., Sigma Aldrich Corporation, Abbott Laboratories, Beckman Coulter, Bio-Rad Laboratories, GE Healthcare, QIAGEN, Becton Dickinson & Company and Thermo Fischer Scientific. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global PCR, Market Overview Chapter 4 Global Polymerase Chain Reaction Market Revenue, by Products, 2012 - 2020 (USD Million) Chapter 5 Global Polymerase Chain Reaction Market Revenue, by End-user, 2012 - 2020 (USD Million) Chapter 6 Global PCR Market Revenue, by Applications, 2012 - 2020 (USD Million) Chapter 7 Global PCR Market Revenue, by Geography, 2012-2020 (USD Million) Chapter 8 Recommendations Chapter 9 Company Profiles - Abbott Laboratories - Affymetrix, Inc. - Agilent Technologies, Inc. - Beckman Coulter, Inc - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - F. Hoffmann-La Roche Ltd. - GE Healthcare - QIAGEN - Sigma-Aldrich Co. LLC. - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/2n...rase_chain
ABT: 48.35 (+1.23), BDX: 144.33 (-1.24), A: 42.71 (-0.18), AFFX: 12.57 (-0.13)
The Best Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Mon Mar 30, 9:19AM CDT
OCR: 84.52 (+3.45), ELLI: 57.00 (-0.45), JCOM: 70.72 (-0.38), CAH: 91.50 (+1.15), AET: 107.95 (-0.41), BABY: 41.64 (+1.71), DFT: 32.24 (-0.18), NLNK: 53.12 (-0.07), HSIC: 141.11 (+1.14), MNK: 122.95 (-2.22), CAVM: 73.16 (+0.39), HAS: 71.73 (-1.82), BCR: 175.09 (+0.24), MCHP: 49.30 (+0.08), MYL: 72.40 (-1.67), NXPI: 102.69 (+1.45), EV: 43.60 (+0.19), NVDA: 22.31 (+0.25), LVLT: 54.24 (-0.04), CBRL: 137.40 (-1.10), MTSI: 34.46 (-0.27), AZO: 693.41 (+2.68), EQIX: 244.78 (+1.00), IRWD: 15.07 (-0.19), AVB: 170.64 (+1.59), KNX: 32.62 (+0.07), HAE: 42.33 (-0.21), FSL: 41.53 (+0.49), FHN: 14.49 (+0.06), BDX: 144.33 (-1.24), ACT: 295.22 (+0.69), F: 15.91 (+0.09), AON: 97.20 (+0.10), NUVA: 43.38 (+0.10), CDW: 38.93 (+0.21), ANTM: 152.84 (-0.04), APH: 56.81 (-1.35), INFA: 47.92 (-0.03), EXAM: 42.52 (-0.16), LII: 107.70 (+2.09), BJRI: 50.54 (-1.00), BDN: 14.90 (+0.14), DPZ: 99.80 (+0.40), FL: 60.00 (-0.08), DLX: 69.57 (+0.47), ABT: 48.35 (+1.23), BMR: 21.37 (+0.14), HCN: 75.44 (+0.21), DIOD: 28.02 (+0.12), LEG: 44.32 (unch), DIS: 107.94 (+0.26), GLW: 22.44 (-0.17), MAR: 80.79 (+0.32), ASML: 107.81 (+10.06), IMAX: 37.51 (+0.51), CNC: 70.90 (+0.12), CTAS: 82.05 (+0.01), FLO: 22.50 (-0.03), CRM: 67.71 (+0.33)
